In a novel ABO-incompatible kidney transplantation, investigators converted the deceased donor kidney’s blood type.

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE ...

Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet ...

New data from Eli Lilly and Company showed Omvoh-treated patients with moderately to severely active ulcerative colitis (UC) and bowel urgency experienced early improvements in bowel urgency severity, ...

Peptides derived from endogenous regulatory proteins are believed to often serve as intriguing molecular probes in neuroscience and related fields.

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen  Omvoh ...

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, (GLOBE ...

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing ...

The Antioxidant Revolution Hidden in Your CupSomething remarkable happens when hot water meets tea leaves. Tea is among the ...

“While FIH studies require cautious interpretation, and rigorous validation, the long-term expression of biologic antibodies ...

BioMarin Pharmaceutical Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ® (pegvaliase-pqpz) supplemental Biologics License ...